Oruka Therapeutics (NASDAQ:ORKA) Earns “Buy” Rating from HC Wainwright

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They presently have a $45.00 price objective on the stock. HC Wainwright’s target price would suggest a potential upside of 116.87% from the company’s current price.

A number of other research firms have also recently commented on ORKA. Wedbush restated an “outperform” rating and issued a $40.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, November 19th. Jefferies Financial Group began coverage on Oruka Therapeutics in a report on Friday, September 13th. They issued a “buy” rating and a $40.00 target price on the stock. Stifel Nicolaus started coverage on Oruka Therapeutics in a report on Friday, October 11th. They set a “buy” rating and a $49.00 price target on the stock. Leerink Partners started coverage on Oruka Therapeutics in a research report on Tuesday, September 17th. They set an “outperform” rating and a $44.00 price objective for the company. Finally, Lifesci Capital began coverage on Oruka Therapeutics in a research report on Monday, September 16th. They set an “outperform” rating and a $41.00 price objective for the company. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Oruka Therapeutics presently has an average rating of “Buy” and a consensus target price of $43.17.

Oruka Therapeutics Stock Up 1.2 %

Shares of ORKA opened at $20.75 on Monday. The firm’s fifty day moving average price is $26.16. The stock has a market cap of $726.25 million, a PE ratio of -3.31 and a beta of 0.87. Oruka Therapeutics has a twelve month low of $18.72 and a twelve month high of $53.88.

Institutional Trading of Oruka Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC purchased a new position in shares of Oruka Therapeutics during the 3rd quarter valued at about $343,000. The Manufacturers Life Insurance Company purchased a new position in shares of Oruka Therapeutics during the 3rd quarter valued at about $1,037,000. Wellington Management Group LLP purchased a new position in shares of Oruka Therapeutics during the 3rd quarter valued at about $2,013,000. Janus Henderson Group PLC purchased a new position in shares of Oruka Therapeutics during the 3rd quarter valued at about $5,840,000. Finally, Redmile Group LLC purchased a new position in shares of Oruka Therapeutics during the 3rd quarter valued at about $10,091,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.